176 related articles for article (PubMed ID: 28639617)
1. Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing.
Friedmann T
Gene Ther; 2017 Sep; 24(9):503-505. PubMed ID: 28639617
[TBL] [Abstract][Full Text] [Related]
2. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.
Singh NN; Howell MD; Androphy EJ; Singh RN
Gene Ther; 2017 Sep; 24(9):520-526. PubMed ID: 28485722
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
Singh NN; Lee BM; DiDonato CJ; Singh RN
Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic approaches for spinal muscular atrophy (SMA).
Scoto M; Finkel RS; Mercuri E; Muntoni F
Gene Ther; 2017 Sep; 24(9):514-519. PubMed ID: 28561813
[TBL] [Abstract][Full Text] [Related]
5. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
Shababi M; Glascock J; Lorson CL
Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
[TBL] [Abstract][Full Text] [Related]
6. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
[TBL] [Abstract][Full Text] [Related]
7. Moving towards treatments for spinal muscular atrophy: hopes and limits.
Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
[TBL] [Abstract][Full Text] [Related]
8. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.
Madocsai C; Lim SR; Geib T; Lam BJ; Hertel KJ
Mol Ther; 2005 Dec; 12(6):1013-22. PubMed ID: 16226920
[TBL] [Abstract][Full Text] [Related]
9. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7.
Staropoli JF; Li H; Chun SJ; Allaire N; Cullen P; Thai A; Fleet CM; Hua Y; Bennett CF; Krainer AR; Kerr D; McCampbell A; Rigo F; Carulli JP
Genomics; 2015 Apr; 105(4):220-8. PubMed ID: 25645699
[TBL] [Abstract][Full Text] [Related]
10. Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next.
Wirth B; Karakaya M; Kye MJ; Mendoza-Ferreira N
Annu Rev Genomics Hum Genet; 2020 Aug; 21():231-261. PubMed ID: 32004094
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
Hammond SM; Abendroth F; Gait MJ; Wood MJA
Methods Mol Biol; 2019; 2036():221-236. PubMed ID: 31410800
[TBL] [Abstract][Full Text] [Related]
12. Disease mechanisms and therapeutic approaches in spinal muscular atrophy.
Tisdale S; Pellizzoni L
J Neurosci; 2015 Jun; 35(23):8691-700. PubMed ID: 26063904
[TBL] [Abstract][Full Text] [Related]
13. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
14. Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy.
Woo CJ; Maier VK; Davey R; Brennan J; Li G; Brothers J; Schwartz B; Gordo S; Kasper A; Okamoto TR; Johansson HE; Mandefro B; Sareen D; Bialek P; Chau BN; Bhat B; Bullough D; Barsoum J
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1509-E1518. PubMed ID: 28193854
[TBL] [Abstract][Full Text] [Related]
15. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA.
Zhang ML; Lorson CL; Androphy EJ; Zhou J
Gene Ther; 2001 Oct; 8(20):1532-8. PubMed ID: 11704813
[TBL] [Abstract][Full Text] [Related]
16. [New treatments for spinal muscular atrophy].
Wurster CD; Günther R
Nervenarzt; 2020 Apr; 91(4):294-302. PubMed ID: 32076758
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Morpholino Antisense Oligonucleotides Targeting the Intronic Repressor Element1 in Spinal Muscular Atrophy.
Osman EY; Washington CW; Kaifer KA; Mazzasette C; Patitucci TN; Florea KM; Simon ME; Ko CP; Ebert AD; Lorson CL
Mol Ther; 2016 Sep; 24(9):1592-601. PubMed ID: 27401142
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.
Brichta L; Hofmann Y; Hahnen E; Siebzehnrubl FA; Raschke H; Blumcke I; Eyupoglu IY; Wirth B
Hum Mol Genet; 2003 Oct; 12(19):2481-9. PubMed ID: 12915451
[TBL] [Abstract][Full Text] [Related]
19. Therapeutics development for spinal muscular atrophy.
Sumner CJ
NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
[TBL] [Abstract][Full Text] [Related]
20. Spinal muscular atrophy: diagnosis and management in a new therapeutic era.
Arnold WD; Kassar D; Kissel JT
Muscle Nerve; 2015 Feb; 51(2):157-67. PubMed ID: 25346245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
